Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2014

View Archived Issues

Clinical phase I/II results of gene therapy for Becker muscular dystrophy

Phase II clinical results for a three-drug combination against HCV infection

GlaxoSmithKline plans phase II study of GSK-2269557 for acute exacerbation of COPD

New antagonists of S1P3 revert neurodegeneration and neuroinflammation

Nippon Kayaku launches infliximab biosimilar in Japan

Osteopontin RNA aptamer shows potential for the treatment of heart failure

LCZ-696 granted accelerated assessment by CHMP in Europe

Fullerene polyaminocaproic acid tested against HSV infection

Medicines for Malaria Venture collaborates with Cipla and Strides

UCB and Daiichi Sankyo partner to commercialize lacosamide in Japan

Aerocrine plans rights issue to fund commercialization of asthma diagnostic

Bukwang Pharmaceutical acquires Contera Pharma

Fingolimod fails to achieve endpoint in phase III trial in PPMS

Rinat Neuroscience discloses new anti-glucagon receptor antibodies

Incyte patents novel JAK-1 inhibitors

Roche patent reports new anti-HBV compounds

New mu opioid receptor antagonists designed at Dr August Wolff

Suzhou Vivotide Biotechnologies discloses novel VEGFR-1 inhibitors

Dynavax regains rights to DV-1179 under GSK collaboration

Mochida seeks approval in Japan for Lexapro in social anxiety disorder

Janssen files for manufacturing and distribution approval for ibrutinib in Japan

MSD and Kyorin sign Japanese comarketing agreement for desloratadine

EMA accepts for review Imbruvica submission for Waldenstrom's macroglobulinemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...